The PennZone

  • Home
  • Non-profit
  • Education
  • Business
  • Technology
  • Construction
  • Entertainment
  • Health
  • Software

Beneficience.com Legacy PR Announces Dr. Burd Renowned Diabetes Scientist, Biochemist-entrepreneur and Dexcom Founder, client
The PennZone/10216335

Trending...
  • XRPPower Continues Strengthening Its Global AI-Powered Blockchain Ecosystem
  • Lansdowne Photographer Steven Weisz Selected for Philadelphia City Hall Exhibition
  • Mutant-Fueled Bio-Cyberpunk Shooter HoverGrease 2 Launches May 22
Beneficience Com Announces Dr John Burd, Renowned Dr John Burd Lysulin© Dr Burd Wonder Spray Skin Rescue 8oz Skin Rescue Lysulin© Products Beneficience.com Legacy PR
Dr. Burd is a renowned diabetes scientist and biochemist and Founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring (CGM) systems. Get to know him and what good he is doing in the world, and for whom his life work benefits.

SAN DIEGO - PennZone -- About John Burd, PhD:

Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc.  In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes.   The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications.  In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.

Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes.  In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million.  In 2020 DexCom had a market cap of over $40 billion.  From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.

Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market.  LXN was sold to Johnson and Johnson in 2000.

More on The PennZone
  • Burkentine Builders Breaks Ground For Two New Communities
  • VIV Welcomes Residents to St. Petersburg's EDGE District
  • Evocative Joins the Independent Data Centre Network (IDCN) as Primary USA Operator
  • Philadelphia Scientist Roohid Parast Advances IBD Research at Johnson & Johnson
  • Medical Experts Highlight the Importance of Second Opinions in Death Investigations

Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance.  MAST Immunosystems was purchased by Hitachi Chemical in 1997.  Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).

Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products.  He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin.  In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.

Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

JOHN F. BURD, Ph.D.

Founder & CEO Lysulin, Inc and Wonder Spray, llc.

More on The PennZone
  • Joseph Nybyk aka Neibich of Gilbert, Arizona
  • Omnitronics Unveils 100% Software omniGateDMR and omniGateP25 RoIP Gateways
  • KRE PRIME Launches Adaptive Convertible Jumpsuit
  • USA Med Bed Helping Home Care Patients with Refurbished Hill Rom Hospital Beds
  • Sobreseimiento de Nicolás dos Santos y Jorge Méndez expone demandas millonarias a Paraguay y boicot a la Hidrovía

4930 Bradshaw Court, San Diego, CA  92130
Phone: 619-992-2873

Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)

Learn more about Dr. Burd's products below...

Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8



Lysulin video:  https://www.youtube.com/watch?v=PK3CkMty6RE



Running A1c test: https://tinyurl.com/y379jbla

Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos

Follow Burd's PR News at http://Beneficience.com

MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd

Contact
Dr. Tracey Bond, MPRL
Certified Publicist of Record
for John Burd, PhD
***@beneficience.com


Source: Beneficience.com Legacy PR
Filed Under: Business, Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Global.ai Appoints Freedomtech Solutions as Specialist Partner for Agentic AI
  • Communities In Schools of Eastern Pennsylvania's Ready, Set, Graduate! Celebrates Over 100 Students in Two Ceremonies
  • Lansdowne Photographer Steven Weisz Selected for Philadelphia City Hall Exhibition
  • Federal indictments bring new scrutiny to SPLC practices and highlight the real‑world impact of its designations on nonprofit groups, including NCFM
  • Shedrack Anderson Releases New Album
  • Could You Make a 2026 World Cup Squad? A New Free Tool Will Tell You Where You'd Sit on Any National Team's Bench in 90 Seconds
  • Sugar Land's Social Scene Gets a Boost: Pep's Backyard Set to Open Near Constellation Field
  • Joseph Nybyk (AKA Joseph Neibich) Guests On Octopus TV
  • Mutant-Fueled Bio-Cyberpunk Shooter HoverGrease 2 Launches May 22
  • Triple-Digit Growth, OTCQX Market Upgrade and a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation: Stock Symbol: CDIX
  • XRPPower Continues Strengthening Its Global AI-Powered Blockchain Ecosystem
  • Lick Introduces Pineapple Flavored Massage Oil — A Tropical Date Night Favorite Available on Amazon
  • FutureLot Powers ADU Wizard for Massachusetts Clean Energy Center's Statewide ADU Resource Center
  • ICT Innovations Releases ICTPBX Community Edition as Open Source Under Mozilla Public License 2.0
  • Brett Furman Expands AI and Marketing Team to Better Help Home Sellers Navigate the Future of Online Search
  • Maryland Personal Injury Firm Earns National Recognition in 2026 ELA Awards
  • Robert J. Bradshaw's AYE is a Gripping Dual Reality Thriller Exploring the Increasingly Blurred Line Between Humanity and Technology
  • Bangxing Silicone Revolutionizes Silicone Baby Product Partnerships: Low MOQ Support + VIP Long-Term Win-Win Programs
  • JFAB Consulting Elevates Brand with New Identity and Digital Experience
  • SteelTree Announces Launch of Its Operational Decision Intelligence Service

Popular on PennZone

  • Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
  • People & Stories/Gente y Cuentos Welcomes Two New Trustees as Organization Enters 54th Year and Expands Community Reach
  • Assymetrix Launches the Deepest Independent Prediction Market Data API
  • AWARENESS TO WELLNESS: Imhotep Institute Charter High School
  • Strategic Talent Associates Launches THE ALIGNED RESET™
  • New plusOne Research Finds the Orgasm Gap Is a 30-Point Chasm — and Confirms It Isn't Biology
  • Resident Inspect Joins Property Meld Nexus Network with API Integration
  • New Homesites Released at Heritage at Manalapan Featuring Scenic Golf Course Views
  • RAS AP Consulting Advances to RFP Stage in Heidelberg Materials' SAP Vendor & Customer Master Data Modernization Initiative
  • Expert E-Bike Safety Advocate Issues Urgent Warning Following Recent Southern California Fatalities

Similar on PennZone

  • Curious About Mensa? DFW Event Offers a 1-Day Immersion
  • VIV Welcomes Residents to St. Petersburg's EDGE District
  • Medical Experts Highlight the Importance of Second Opinions in Death Investigations
  • KRE PRIME Launches Adaptive Convertible Jumpsuit
  • USA Med Bed Helping Home Care Patients with Refurbished Hill Rom Hospital Beds
  • Sobreseimiento de Nicolás dos Santos y Jorge Méndez expone demandas millonarias a Paraguay y boicot a la Hidrovía
  • CAPHRA warns Southeast Asia not to repeat Australia's nicotine policy failure
  • UK Financial Ltd Executes 100% Success Rate on All ERC-3643 Transfers to Coin Holders of MayaCat Regulated Security Token and Maya Preferred PRA
  • Blank Space: The Unofficial Taylor Swift Tribute Brings Eras Tour Magic To Cities Across America
  • D.R. Crotzer Announces A New Science Fiction Book Series Exploring Life Energy, Dreams, and the Mystery of Existence
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us